A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

Antonio Gonzalez Martin,Florian Heitz,René Depont Christensen,Frederic Selle,Nicoletta Colombo,Carmen Marqués,Toon Van Gorp,Javier Sanchez,Luisa Sanchez Lorenzo,Nuria Alvarez,Mihai Meirovitz

doi:10.1136/ijgc-2020-001633

A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

Antonio Gonzalez Martin, Florian Heitz + Show 9 more

https://doi.org/10.1136/ijgc-2020-001633

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Dec 14, 2020
Citations: 23

Affiliation: Kliniken Essen-Mitte, University of Southern Denmark, European Institute of Oncology, University of Milan, Universitair Ziekenhuis Leuven, Clinica Universidad de Navarra

#Maintenance Niraparib #Synergy In Preclinical Models + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPlatinum based chemotherapy is the treatment of choice for ovarian cancer patients with a platinum treatment free interval of >6 months. Niraparib is an oral poly (ADP-ribose) polymerase inhibitor approved...

Full Text